hMOB2 deficiency impairs homologous recombination-mediated DNA repair and sensitises cancer cells to PARP inhibitors by Gundogdu, R, Erdogan, MK, Ditsiou, A, Spanswick, V, Garcia-Gomez, JJ, Hartley, JA, Esashi, F, Hergovich, A, Gomez, V

Preliminary results of a Cancer Research UK phase I trial combining the dinitrobenzamide prodrug CB1954 (tretazicar) and the NQO2 substrate EP-0152R (caricotamide) by Sarker, D, Anderson, D, Spanswick, V, Davies, S, Agarwal, R, Aitken, G, Kerr, D, Hartley, J, Judson, I, Middleton, MR

Quinone oxidoreductase-2-mediated prodrug cancer therapy. by Middleton, MR, Knox, R, Cattell, E, Oppermann, U, Midgley, R, Ali, R, Auton, T, Agarwal, R, Anderson, D, Sarker, D, Judson, I, Osawa, T, Spanswick, V, Davies, S, Hartley, J, Kerr, D